SCWorx Corp. Secures Nasdaq Listing Following Private Placement

MIDDLETON, Mass, Oct. 05, 2026 /CourierPR/ -- SCWorx Corp., a provider of data management solutions to healthcare providers, has secured a significant victory in its battle to remain listed on The Nasdaq Capital Market. On October 2, 2026, the Nasdaq Hearings Panel granted the company's request for reconsideration of a September 17, 2026, decision to delist its common stock from The Nasdaq Stock Market LLC. The panel's decision came after the company's September 16, 2026, private placement, which, along with the exercise of outstanding warrants, increased the company's publicly held shares to 549,092 shares as of September 17, 2026, surpassing the 500,000-share minimum required by Nasdaq Listing Rule 5550(a)(4).

The company's closing bid price has remained at or above $1.00 per share since August 4, 2026, including the 10 consecutive trading days following September 17, 2026, as required under Nasdaq Listing Rule 5810(c)(3)(A). This continuous compliance with the minimum bid price requirement, coupled with the increase in publicly held shares, led to the Nasdaq Listing Qualifications Staff confirming that SCWorx had regained compliance with the publicly held shares requirement on September 30, 2026.

Trading in the company's common stock, which had been suspended since April 14, 2026, is set to be reinstated on a date to be scheduled by Nasdaq. The company is currently submitting its Nasdaq reinstatement form and expects to announce the reinstatement date once it is confirmed by Nasdaq. Until trading on Nasdaq is reinstated, the company's common stock will continue to be quoted on the OTCQB Venture Market under the symbol "WORX."

As a condition of continued listing, the panel required SCWorx to publicly disclose that each investor in the September 2026 private placement has agreed not to exercise its contractual right under the securities purchase agreement to terminate its purchase based on the Panel's September 17, 2026, decision. Each of the investors has delivered that agreement to the company. The panel also imposed a Discretionary Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(A) for a one-year period ending October 2, 2027, and required the company to provide monthly reports of its shares outstanding, insider holdings, and public float to Nasdaq through October 5, 2027. If Nasdaq determines that the company fails any continued listing standard during the monitor period, the company will not be permitted to submit a compliance plan or receive a cure or compliance period, and Nasdaq will promptly issue a Staff Delisting Determination, which the company would be entitled to appeal to a Hearings Panel.

The company's solutions are designed to improve the accuracy, standardization, and utilization of healthcare supply-chain data, supporting healthcare organizations in managing their item master and related supply-chain information.